Here are a couple of strong ASX 200 shares that have been given buy ratings by brokers recently. Let's find out ...

From office conversions to co-living, housing providers are delivering unique ways to deliver much needed housing supply in coveted urban areas.

With CSL Ltd (ASX: CSL) shares forecast to grow profits by up to 13% following a strong FY 2024, this expert thinks they’re a ...

The Pharmaceutical Automation and Digitalisation Congress (AUTOMA+) 2024 is a strategic platform for discussion and ...

The complement inhibitors market is gaining momentum due to the rising recognition of the complement system's role in driving rare and chronic diseases, such as paroxysmal nocturnal hemoglobinuria ...

Blood products giant CSL says current-year earnings should be 10-13% higher as it looks to taper capital expenditure.

Popular GLP-1 drugs are already known to have many benefits, but scientists continue to explore what else they — and their ...

The findings of the two studies were not unexpected, Mustafa said. “Heterogeneity in medical care is well recognized in ...

Brokers gave buy ratings to these ASX shares last week. Why are they bullish? The post Top brokers name 3 ASX shares to buy ...

UBS analyst Laura Sutcliffe maintained a Buy rating on CSL (CMXHF – Research Report) today and set a price target of A$340.00. The ...

Citi analyst Mathieu Chevrier maintained a Buy rating on CSL (CMXHF – Research Report) today and set a price target of A$345.00. The ...

Funk has received scientific grants, congress invitations, or speaker/consultant fees from Amgen, Astra Zeneca, Bristol Myers Squibb, Boehringer Ingelheim, Chiesi, CSL Behring, Daiichi Sankyo, Draeger ...